Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancer

Clinical Lung Cancer

Volumn 3, Issue 3, 2002, Pages 213-218

  Lloyd, Katherine P ^a   Krystal, Geoffrey W ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Kit; Stem cell factor; STI574; SU5416; Tyrosine kinase

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANTIMETABOLITE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; INTERFERON; IRINOTECAN; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; QUINOXALINE DERIVATIVE; QUINOXALINE TYRPHOSTIN; SEMAXANIB; STEM CELL FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VATALANIB; VINCRISTINE;

ARTICLE; BIOLOGY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOXICITY; EDEMA; HUMAN; LUNG SMALL CELL CANCER; MEDICAL DOCUMENTATION; MOLECULAR SIZE; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; PROGNOSIS; THROMBOCYTOPENIA;

EID: 0036200080     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.n.005     Document Type: Article

References (63)

1. Small cell lung cancer
2. Extensive-disease small-cell lung cancer: The thrill of victory; the agony of defeat
3. Management of small cell lung cancer: Current state of the art
4. Chemotherapy of lung cancer
5. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
6. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
7. Increased dose-intensity in small-cell lung cancer: A failed strategy?
8. New chemotherapy agents for small cell lung cancer
9. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma
10. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group
11. Molecular biology of lung cancer
12. Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs
13. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells
14. Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro
15. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide
16. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
17. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro
18. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue
19. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells
20. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines
21. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer
22. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts
23. C-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines
24. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer
25. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues
26. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues
27. Stem cell factor and hematopoiesis
28. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene
29. Lysophosphatidic acid-depleted serum, hepatocyte growth factor and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway
30. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor
31. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins
32. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
33. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
34. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
35. Activating c-kit gene mutations in human germ cell tumors
36. The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia
37. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells
38. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors
39. Loss of c-kit expression in cultured melanoma cells
40. Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene
41. C-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells
42. Coexpression of the c-kit and stem cell factor genes in breast carcinomas
43. Oncogenic kinase signalling
44. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents
45. The EGF receptor family as targets for cancer therapy
46. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
47. Tyrosine kinase inhibition: An approach to drug development
48. Protein kinase inhibitors: Structural determinants for target specificity
49. ATP site-directed competitive and irreversible inhibitors of protein kinases
50. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
51. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
52. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
53. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
54. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
55. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
56. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
57. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
58. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
59. SU6668 is a potent antiangiogenic and anti-tumor agent that induces regression of established tumors
60. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells
61. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
62. Effect of the tyrosine kinase inhibitor imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor
63. Dose finding study of cisplatin, gemcitabine, and SU-5416 in patients with advanced malignancies